Chronic Obstructive Pulmonary Disease Virtual Reality Therapy Market Report 2026

The chronic obstructive pulmonary disease virtual reality therapy market size has grown rapidly in recent years. It will grow from $1.38 billion in 2025 to $1.65 billion in 2026 at a compound annual growth rate (CAGR) of 19.5%. The growth in the historic period can be attributed to expansion of pulmonary rehabilitation programs, rising prevalence of copd globally, increased adoption of non-pharmacological therapies, growth of digital health platforms, availability of vr hardware in clinical settings.

The chronic obstructive pulmonary disease virtual reality therapy market size is expected to see rapid growth in the next few years. It will grow to $3.33 billion in 2030 at a compound annual growth rate (CAGR) of 19.3%. The growth in the forecast period can be attributed to increasing demand for remote respiratory care solutions, rising investments in immersive digital therapeutics, expansion of homecare pulmonary management, growing integration of ai-driven therapy personalization, increasing focus on patient adherence and engagement. Major trends in the forecast period include increasing adoption of home-based vr pulmonary therapy, rising integration of gamified rehabilitation programs, growing use of remote patient monitoring tools, expansion of immersive respiratory training modules, enhanced focus on patient engagement.

The growing awareness and acceptance of virtual reality therapy are expected to drive the expansion of the chronic obstructive pulmonary disease virtual reality therapy market. Virtual reality therapy uses immersive technology to create interactive environments for treatment and rehabilitation. Its increased adoption is fueled by evidence of its effectiveness in reducing pain and anxiety, providing patients with a non-invasive, drug-free option that enhances treatment experience and outcomes. Greater awareness supports COPD virtual reality therapy by educating patients and providers, promoting digital rehabilitation solutions, and improving treatment engagement through familiarization with immersive therapies, which encourages adherence and better health outcomes. For example, in July 2024, the U.S. Department of Veterans Affairs deployed approximately 3,500 VR headsets across more than 170 medical centers and outpatient clinics, tripling the number available for therapeutic use. Consequently, rising awareness and acceptance are contributing to market growth.

The increasing focus on personalized medicine is also expected to fuel growth in the chronic obstructive pulmonary disease virtual reality therapy market. Personalized medicine involves tailoring treatment and prevention strategies to an individual’s genetic profile, lifestyle, and environment. Advances in genomics have enabled precise identification of genetic variations, allowing treatments to be customized for each patient. In COPD virtual reality therapy, personalized medicine allows rehabilitation programs to be adapted to individual patient needs, improving treatment effectiveness and targeting specific symptoms, capabilities, and preferences. This enhances patient engagement and adherence. For instance, in February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, up from 12 in 2022. Therefore, the emphasis on personalized medicine is driving market growth by enabling tailored and effective VR therapy interventions.

In March 2025, Wellinks Inc., a US-based digital healthcare company, partnered with CareAbout Health to expand virtual-first COPD management programs within value-based care networks. This collaboration aims to improve patient outcomes, reduce hospitalizations, and increase access to comprehensive, home-based pulmonary care. CareAbout Health, a US healthcare management company, supports virtual COPD care programs, making this partnership a strategic step to enhance VR therapy capabilities.

Major companies operating in the chronic obstructive pulmonary disease virtual reality therapy market are Inova Health System, Rush University Medical Center, Penumbra Inc., Burke Rehabilitation Hospital, MindMaze SA, XRHealth Inc., Jolly Good Inc., AppliedVR Inc., Carda Health Inc., Lincare Inc., Virtually Better Inc., Wellinks Inc., Breathe Better Rehab, Kivo Health Inc., VRelax B.V., Kaia Health GmbH, Philips Healthcare, ResMed Inc., NuvoAir AB, Cohero Health Inc.

North America was the largest region in the chronic obstructive pulmonary disease virtual reality therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease virtual reality therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic obstructive pulmonary disease virtual reality therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the chronic obstructive pulmonary disease virtual reality therapy market by increasing costs of imported virtual reality headsets, motion sensors, haptic devices, and specialized software platforms. Healthcare providers in North America and Europe are most affected due to reliance on imported VR hardware and advanced electronics, while Asia-Pacific faces cost pressures on device manufacturing and exports. These tariffs are raising implementation costs for hospitals and homecare providers. At the same time, they are encouraging localized hardware assembly, domestic software development, and regional partnerships that support scalable and cost-optimized VR therapy solutions.

The chronic obstructive pulmonary disease virtual reality therapy market research report is one of a series of new reports that provides chronic obstructive pulmonary disease virtual reality therapy market statistics, including chronic obstructive pulmonary disease virtual reality therapy industry global market size, regional shares, competitors with a chronic obstructive pulmonary disease virtual reality therapy market share, detailed chronic obstructive pulmonary disease virtual reality therapy market segments, market trends and opportunities, and any further data you may need to thrive in the chronic obstructive pulmonary disease virtual reality therapy industry. This chronic obstructive pulmonary disease virtual reality therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic obstructive pulmonary disease virtual reality therapy is a non-pharmacological treatment approach that uses immersive virtual reality environments to support respiratory rehabilitation, enhance lung function, and boost patient engagement. It integrates interactive exercises, breathing techniques, and real-time feedback to help patients manage symptoms and improve overall quality of life. This therapy is increasingly incorporated into digital health solutions for both home-based and clinical pulmonary care.

The key components of chronic obstructive pulmonary disease virtual reality therapy include hardware, software, and services. Hardware consists of virtual reality headsets, sensors, wearables, and other devices that deliver interactive, immersive therapies for pulmonary rehabilitation, breathing exercises, and symptom management in COPD patients. The therapy includes types such as immersive and non-immersive virtual reality, and is applied in areas like pulmonary rehabilitation, patient education, pain management, anxiety and stress reduction, among others. End-users include hospitals, clinics, home care settings, and other healthcare environments.

The chronic obstructive pulmonary disease virtual reality therapy market consists of revenues earned by entities by providing services such as virtual pulmonary rehabilitation programs, guided breathing and relaxation sessions, remote respiratory therapy, patient education and training modules, tele-rehabilitation support, gamified exercise sessions, and social interaction platforms. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic obstructive pulmonary disease virtual reality therapy market also includes sales of virtual reality (VR) headsets, motion controllers, haptic feedback devices, specialized respiratory training software, cloud-based therapy platforms, and virtual reality (VR)-enabled monitoring systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.